Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
70 hedge funds and large institutions have $141M invested in Sierra Oncology, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 16 closing their positions.
38% more capital invested
Capital invested by funds: $103M → $141M (+$38.8M)
4% less funds holding
Funds holding: 73 → 70 (-3)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
22% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 18
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $30K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$5.28M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.22M |
| 3 |
Morgan Stanley
New York
|
+$1.48M |
| 4 |
Alkeon Capital Management
New York
|
+$953K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$721K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.35M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.08M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$1.84M |
| 4 |
PA
Perceptive Advisors
New York
|
-$1.25M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.18M |
SRRA Hedge Fund Activity: Q2 2018 in Review
70 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q2 2018, worth a combined $141M — up 38% from $103M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of SRRA and 14 opened new positions — a net loss of 2 holders — while 18 trimmed existing stakes and 14 added.
The largest buyer was Broadfin Capital, opening a new position worth an estimated $5.28M. The largest seller was OrbiMed, cutting an estimated $2.35M.
- 70 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q2 2018, down from 73 in Q1 2018.
- Funds reported $141M of Sierra Oncology, Inc. Common Stock stock for Q2 2018, up 38% quarter-over-quarter.
- 14 funds opened new Sierra Oncology, Inc. Common Stock positions in Q2 2018 and 16 closed out, a net change of -2 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q2 2018 was Broadfin Capital, an estimated $5.28M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q2 2018 was OrbiMed, an estimated $2.35M sold.
Based on aggregated 13F filings for Q2 2018.